Mercado mundial de conjuntivitis bacteriana: tendencias de la industria y pronóstico hasta 2029

Análisis y tamaño del mercado                              

La conjuntivitis, conocida popularmente como ojo rosado en los Estados Unidos, es una infección ocular contagiosa. La conjuntivitis bacteriana es una irritación conjuntival que pueden causar bacterias, virus o alergias . Es una enfermedad altamente contagiosa que se propaga rápidamente de una persona a otra al tocar las cosas de personas infectadas, toser y estornudar. Las bacterias grampositivas y gramnegativas pueden causar conjuntivitis bacteriana. Algunos de los síntomas incluyen enrojecimiento de los ojos, lágrimas en movimiento, secreción espesa y amarillenta, picazón, sensación de ardor, visión borrosa y mayor sensibilidad a la luz.

Data Bridge Market Research analiza que el mercado de la conjuntivitis bacteriana se valoró en USD 4.18 mil millones en 2021 y se espera que alcance los USD 5.81 mil millones para 2029, registrando una CAGR del 4,20% durante el período de pronóstico de 2022 a 2029. Además de los conocimientos del mercado, como el valor de mercado, la tasa de crecimiento, los segmentos del mercado, la cobertura geográfica, los actores del mercado y el escenario del mercado, el informe de mercado curado por el equipo de Data Bridge Market Research también incluye un análisis de expertos en profundidad, epidemiología del paciente, análisis de la cartera, análisis de precios y marco regulatorio.

Alcance del informe y segmentación del mercado

Market Definition

Inflammation of the outermost layer of the eye and the inner area of the eyelid is known as bacterial conjunctivitis. Swelling, wet eyes, and redness are all indications of bacterial conjunctivitis. Staphylococci, haemophilus, Chlamydia trachomatis, and streptococci are among the bacteria that cause conjunctivitis. Bacterial conjunctivitis is more common in children and the elderly, but it can afflict persons of any age range. The rising number of occurrences of bacterial conjunctivitis necessitates effective treatment, boosting the market for bacterial conjunctivitis medications. Immunological compromise, poor hygiene, ocular diseases such as blepharitis, dry eye and contaminated cosmetics all contribute to the spread of bacterial conjunctivitis. It can be avoided by keeping good hygiene, and hand washing help to lower the risk of bacterial conjunctivitis.

Bacterial Conjunctivitis Market Dynamics

Drivers

• Rising prevalence of bacterial conjunctivitis

The rising prevalence of bacterial conjunctivitis is anticipated to expand the market's growth rate. Conjunctivitis is on the rise around the world, with a large increase in the incidence and prevalence rate. Conjunctivitis affects millions of individuals worldwide, putting a financial and social strain on growing economies like China, India, and Korea. It is widely used in the United States, China, India, and other EU countries. According to the National Center for Biotechnology Information, acute conjunctivitis affects about 6 million people in the United States each year. Treatment for bacterial conjunctivitis is expected to cost between USD 377 and USD 857 million per year. Many state health agencies in the United States require students to be treated with topical antibiotic eye drops before returning to school, regardless of the underlying cause of conjunctivitis.

• Improved eye care system in hospitals and clinics globally

Conjunctivitis is treated effectively in all hospitals and clinics. It is unnecessary to seek treatment for conjunctivitis at a specialized eye hospital. The majority of conjunctivitis patients are treated by general care physicians rather than specialized eye care professionals. Conjunctivitis accounts for about 1% of all primary care office visits in the United States. A total of 70.0 percent of patients with acute conjunctivitis are treated in primary care and urgent care settings. Patients can receive specialist care from a variety of eye care hospitals, clinics, and research institutes, among others.

• Increasing cases of conjunctivitis in infants

The increasing number of cases of conjunctivitis in infants is estimated to enhance the market's growth rate. A large number of new-borns are affected with bacterial conjunctivitis. New-borns with this syndrome are particularly vulnerable to catastrophic consequences. As a result, treatment for this ailment cannot be postponed. All of the major hospitals, clinics, and institutes actively assist the treatment of new-borns as soon as possible. After a baby develops conjunctivitis, ointment or prescribed eye drops are recommended. Chemical, bacterial, inclusion, and even childhood conjunctivitis are other types of conjunctivitis in new-borns that can go away in a few weeks under the guidance of a specialist.

Furthermore, a surging number of government initiatives to spread awareness and sedentary lifestyle will result in the expansion of bacterial conjunctivitis market. Along with this, rising level of disposable income and increased exposure to chemicals and pollutants will enhance the market's growth rate.

Opportunities

• Increasing investment for healthcare infrastructure

Another significant factor influencing the growth rate of bacterial conjunctivitis market is the rising healthcare expenditure which helps in improving its infrastructure. Government policies all around the world are focusing on strengthening the healthcare system by boosting healthcare budgets and creating consistent policies. Governments all throughout the world are supporting the healthcare system. The world's healthcare system has benefited from increased healthcare spending. Developed economies, such as the U.S., U.K., Germany, and Canada, invest substantial money in healthcare. China, Korea, India, and Korea are among the growing economies that are expanding their healthcare spending.

• Rise in R&D activities  

The market's growth is fueled by growing number of research and development activities. This will provide beneficial opportunities for the bacterial conjunctivitis market growth.

Moreover, the market's growth is fueled by investment to develop advanced technologies and increase the number of emerging markets. These factors will provide beneficial opportunities for the bacterial conjunctivitis market growth.

Restraints/Challenges

On the other hand, the high cost associated with the treatment will obstruct the growth rate of bacterial conjunctivitis market during the forecast period of 2022-2029. The patent expiry of branded drugs and introduction of generic drugs will challenge the bacterial conjunctivitis market. Additionally, lack of healthcare infrastructure in developing economies and the dearth of awareness among people will act as restrain and further impede the growth rate of market during the forecast period of 2022-2029.

This bacterial conjunctivitis market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the bacterial conjunctivitis market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Patient Epidemiology Analysis

Bacterial conjunctivitis market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period. 

COVID-19 Impact on Bacterial Conjunctivitis Market

In order to contain the coronavirus outbreak, most of the world's main nations were compelled to go into lockdown. Since then, the pandemic has delayed the expansion of the healthcare sector and disrupted the supply chain. Furthermore, governments in many nations had imposed nationwide lockdowns to halt the spread of COVID-19. As a result of this predicament, most pharmaceutical companies throughout the world are focusing on preserving their commerce and cash flow rather than investing in product development. Key players in the global conjunctivitis sector were also having difficulty running their plants and working at full capacity in order to meet their production targets. However, the bacterial conjunctivitis market is likely to improve as respective government bodies lifted the enforced lockdown restrictions. Various sectors are anticipated to rebound quickly post COVID-19 pandemic due to the wide number of applications they serve. As a result, the market is projected to stabilize in the future.

Global Bacterial Conjunctivitis Market Scope

The bacterial conjunctivitis market is segmented on the basis of types, drug class, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Drug Class

• Antibiotics
• Fluoroquinolones
• Aminoglycosides
• Macrolides
• Others
• Antihistamines
• Corticosteroids
• Others

Types

• Hyperacute Bacterial Conjunctivitis
• Acute Bacterial Conjunctivitis
• Chronic Bacterial Conjunctivitis

Route of Administration

• Oral
• Topical
• Others

End-Users

• Hospitals
• Specialty Clinics
• Homecare
• Others

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

Bacterial Conjunctivitis Market Regional Analysis/Insights

The bacterial conjunctivitis market is analysed and market size insights and trends are provided by country, types, drug class, route of administration, end-users and distribution channel as referenced above.

The countries covered in the bacterial conjunctivitis market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

North America and Europe dominate the bacterial conjunctivitis market because of the rising healthcare expenditure and increasing prevalence of conjunctivitis cases in this region. Additionally, the growing focus of major key players in research and development activities will further propel the market's growth rate.

Asia-Pacific is expected to be the fastest-growing region during the forecast period of 2022-2029 due to the growing number of patient populations and the large number of generic manufacturers in this region. Also, development of healthcare infrastructure and rising government initiatives will further propel the market's growth rate in this region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Análisis del panorama competitivo y de la cuota de mercado de la conjuntivitis bacteriana

El panorama competitivo del mercado de la conjuntivitis bacteriana proporciona detalles por competidor. Los detalles incluidos son una descripción general de la empresa, las finanzas de la empresa, los ingresos generados, el potencial de mercado, la inversión en investigación y desarrollo, las nuevas iniciativas de mercado, la presencia global, los sitios e instalaciones de producción, las capacidades de producción, las fortalezas y debilidades de la empresa, el lanzamiento de productos, la amplitud y la variedad de productos, el dominio de las aplicaciones. Los puntos de datos anteriores proporcionados solo están relacionados con el enfoque de las empresas en relación con el mercado de la conjuntivitis bacteriana.

Algunos de los principales actores que operan en el mercado de la conjuntivitis bacteriana son:

• Eli Lilly and Company (Estados Unidos)
• AstraZeneca (Reino Unido)
• Novartis AG (Suiza)
• Johnson & Johnson Private Limited (Estados Unidos)
• Teva Pharmaceutical Industries Ltd. (Irlanda)
• Merck & Co., Inc. (Estados Unidos)
• Allergan (Irlanda)
• Bausch Health Companies Inc. (Canadá)
• Abbott (Estados Unidos)
• F. Hoffmann-La Roche Ltd. (Suiza)
• Pfizer Inc. (Estados Unidos)
• GlaxoSmithKline plc (Reino Unido)
• Sanofi (Francia)
• Merck KGaA (Alemania)
• Industrias farmacéuticas Sun Ltd. (India)
• Endo International plc (Irlanda)
• Apotex Inc. (Canadá)
• Amneal Pharmaceuticals LLC. (Estados Unidos)
• Fresenius Kabi AG (Alemania)
• Torrent Pharmaceuticals Ltd. (India)

SKU-53443